Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy.

被引：0
|
作者：
Sinn, Bruno Valentin
Von Minckwitz, Gunter
Denkert, Carsten
Eidtmann, Holger
Darb-Esfahani, Silvia
Belau, Antje
Kronenwett, Ralf
Holzhausen, Hans-Juergen
Mehta, Keyur
Loibl, Sibylle
机构：
[1] Charite, D-13353 Berlin, Germany
[2] German Breast Grp, Neu Isenburg, Germany
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany
[5] Sividon Diagnost GmbH, Cologne, Germany
[6] Univ Halle Wittenberg, D-06108 Halle, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
522
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
    Sinn, B. V.
    von Minckwitz, G.
    Denkert, C.
    Eidtmann, H.
    Darb-Esfahani, S.
    Tesch, H.
    Kronenwett, R.
    Hoffmann, G.
    Belau, A.
    Thommsen, C.
    Holzhausen, H. J.
    Grasshoff, S. T.
    Baumann, K.
    Mehta, K.
    Dietel, M.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2316 - 2324
  • [2] MUCIN-1 PROTEIN AND MRNA EXPRESSION IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY
    Sinn, B. V.
    von Minckwitz, G.
    Denkert, C.
    Eidtmann, H.
    Darb-Esfahani, S.
    Belau, A.
    Kronenwett, R.
    Holzhausen, H.
    Mehta, K.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 17 - 17
  • [3] Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.
    Liu, Ying
    Saraf, Anurag
    Lee, Shing Mirn
    Zhong, Xiaobo
    Kalinsky, Kevin
    Connolly, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Survival and recurrence of breast cancer patients with pathologic complete response after neoadjuvant chemotherapy.
    Lee, Young Joo
    Ahn, Sei-Hyun
    Sohn, Byung Ho
    Lee, Jong Won
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Hee Jeong
    Kim, Jisun
    Lee, Sae Byul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer
    Götte, M
    Kersting, C
    Ruggiero, M
    Tio, J
    Tulusan, AH
    Kiesel, L
    Wülfing, P
    ANTICANCER RESEARCH, 2006, 26 (1B) : 621 - 627
  • [6] Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
    Liu, Ying
    Catanese, Benjamin Peter
    Chin, Christine
    Lee, Shing
    Zhan, Serena
    Kalinsky, Kevin
    Connolly, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Predictive biomarkers of survival after neoadjuvant chemotherapy for breast cancer
    Galvez-Nino, Marco
    Roque, Katia
    Angel Bernabe, Luis
    Castillo, Miluska
    Sanchez, Joselyn
    Landa Baella, Maria
    Calderon, Gabriela
    De la Cruz, Miguel
    Dunstan, Jorge
    Abugatas, Julio
    Cotrina, Jose
    Castaneda, Carlos
    Gomez, Henry
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
    Ziping Wu
    Lei Zhang
    Shuguang Xu
    Yanping Lin
    Wenjin Yin
    Jinglu Lu
    Rui Sha
    Xiaonan Sheng
    Liheng Zhou
    Jinsong Lu
    Cancer Cell International, 19
  • [9] Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
    Wu, Ziping
    Zhang, Lei
    Xu, Shuguang
    Lin, Yanping
    Yin, Wenjin
    Lu, Jinglu
    Sha, Rui
    Sheng, Xiaonan
    Zhou, Liheng
    Lu, Jinsong
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [10] Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer
    Kneubil, M. C.
    Goulart, K. O. B.
    Brollo, J.
    Coelho, G. P.
    Mandelli, J.
    Orlandin, B. C.
    Corso, L. L.
    Roesch-Ely, M.
    Henriques, J. A. P.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2022, 55 (01)
12345